HWPC(SH:688799) Zheng Quan Zhi Xing·2025-05-12 12:25Core Viewpoint - The company plans to invest up to RMB 10 million in the Suzhou Rongxin Health Industry Venture Capital Center (Limited Partnership), focusing on innovative pharmaceutical products and technologies, which aligns with its main business [1][2]. Investment Overview - The investment aims to leverage the expertise of professional investment institutions to identify early-stage investment opportunities in high-potential areas such as innovative pharmaceuticals and complex formulations [2]. - The company will not guarantee minimum returns or exit guarantees for other investors in the fund [2]. Fund Management - The fund will be managed by Suzhou Rongshi Private Equity Fund Management Co., Ltd., which has a registered capital of RMB 10 million and manages funds ranging from RMB 1 billion to 2 billion [3]. - The fund is currently in the preparation and fundraising stage, with other partners yet to be fully determined [4]. Agreement and Compliance - As of the announcement date, the partnership agreement has not been signed, and the specifics will be determined by the final agreement [4]. - The investment does not constitute a related party transaction or a major asset restructuring as per regulatory definitions [2]. Financial Impact - The investment will not be consolidated into the company's financial statements and will not impose financial pressure on the company's existing operations [4]. - The funding source for the investment is the company's own funds, ensuring that normal business operations remain unaffected [4]. Risk Analysis - The investment process carries uncertainties, including the potential failure to raise sufficient funds due to partners not fulfilling their capital commitments [5]. - The company, as a limited partner, will have limited control over the fund's investment risks and will enhance communication with partners to monitor fund operations [5].